Why the study?
Current heart failure treatments mainly ease symptoms without stopping disease progression, prompting exploration of calcium regulation and altered calcium sensitivity as therapeutic targets across heart failure phenotypes.
Design
Review
Authors
Loading...
Ca2+ sensitization warrants arrhythmia vigilance in HF trials; leaves open optimal myofilament targeting balancing systolic gains and diastolic risks.
Targeting myofilament calcium sensitivity represents a promising but complex therapeutic avenue for heart failure that must balance systolic benefits against diastolic and arrhythmic risks.
Saad et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: